Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) EBT (2022 - 2025)

Prokidney (PROK) has disclosed EBT for 4 consecutive years, with -$35.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 18.69% to -$35.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$155.5 million, a 14.3% decrease, with the full-year FY2024 number at -$163.9 million, down 26.64% from a year prior.
  • EBT was -$35.3 million for Q3 2025 at Prokidney, up from -$36.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$18.9 million in Q4 2023 to a low of -$66.5 million in Q1 2022.
  • A 4-year average of -$36.6 million and a median of -$35.6 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 46.47% in 2023, then plummeted 147.09% in 2024.
  • Prokidney's EBT stood at -$25.8 million in 2022, then rose by 26.72% to -$18.9 million in 2023, then tumbled by 147.09% to -$46.8 million in 2024, then increased by 24.58% to -$35.3 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's EBT are -$35.3 million (Q3 2025), -$36.1 million (Q2 2025), and -$37.4 million (Q1 2025).